tbuckley/cabot-search huggingface dataset:
Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors
Authors: Matthew H Taylor, Aung Naing, John Powderly, Paul Woodard, Luke Chung, Wen Hong Lin, Hongyu Tian, Nathan Siemers, Hong Xiang, Rong Deng, Kyu Hong, Donna Valencia, Tao Huang, Ying Zhu, X Charlene Liao, Xiao Min Schebye, Manish R Patel
Journal: Journal for ImmunoTherapy of Cancer (2024)

Purpose In this first-in-human dose escalation study, the safety and efficacy of IO-108, a fully human monoclonal antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2), was investigated in patients with advanced solid tumors as monotherapy and in combination with pembrolizumab, an anti-programmed cell death protein 1 (PD-1) antibody. Methods The study included patients with histologically or cytologically confirmed advanced and relapsed solid tumors, with measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) V.1.1. Patients were treated with escalating doses of IO-108 every 3 weeks (Q3W) as monotherapy and in combination with pembrolizumab. Safety and tolerability were the primary objectives. Secondary and exploratory objectives included: pharmacokinetics, clinical efficacy, immunogenicity and biomarkers. Results Of 25 patients enrolled, 12 were treated with IO-108 monotherapy and 13 received combination therapy. IO-108 was well-tolerated up to the maximally administered dose of 1,800 mg every 3 weeks (Q3W) as monotherapy and in combination with pembrolizumab. No dose-limiting toxicity was observed, and a maximum tolerated dose was not reached. Treatment-related adverse events (TRAEs) occurred in 6 (50.0%) patients treated with IO-108 monotherapy and 6 (46.2%) patients treated with IO-108+pembrolizumab. All TRAEs were mild or moderate (Grade 1 or 2), and no TRAEs led to treatment discontinuation or death. IO-108 exhibited a dose-proportional increase in exposure. Full receptor occupancy (RO) in peripheral blood was achieved at doses ≥600 mg. The overall response rate was 9% (1/11) in the monotherapy and 23% (3/13) in the combination therapy. A patient with treatment-refractory Merkel cell carcinoma treated with IO-108 monotherapy achieved a durable complete response (CR) for more than 2 years. Pharmacodynamic gene expression changes reflecting increased tumor infiltration of T cells were associated with clinical benefits in both monotherapy and combination therapy. Additionally, baseline tumor inflammation gene signature (TIS) scores correlated with clinical benefit. Conclusion IO-108 is well tolerated and has led to objective response as monotherapy and in combination with pembrolizumab. The complete response and the pharmacodynamic changes in the monotherapy cohort demonstrate single agent activity of IO-108 and provide proof of concept that targeting myeloid-suppressive pathways through LILRB2 inhibition may potentiate the clinical efficacy of anti-PD-1 immune checkpoint inhibitors. Trial registration number NCT05054348 .
Adjunctive Middle Meningeal Artery Embolization for Subdural Hematoma
Authors: Jason M. Davies, Jared Knopman, Maxim Mokin, Ameer E. Hassan, Robert E. Harbaugh, Alexander Khalessi, Jens Fiehler, Bradley A. Gross, Ramesh Grandhi, Jason Tarpley, Walavan Sivakumar, Mark Bain, R. Webster Crowley, Thomas W. Link, Justin F. Fraser, Michael R. Levitt, Peng Roc Chen, Ricardo A. Hanel, Joe D. Bernard, Mouhammad Jumaa, Patrick Youssef, Marshall C. Cress, Mohammad Imran Chaudry, Hakeem J. Shakir, Walter S. Lesley, Joshua Billingsley, Jesse Jones, Matthew J. Koch, Alexandra R. Paul, William J. Mack, Joshua W. Osbun, Kathleen Dlouhy, Jonathan A. Grossberg, Christopher P. Kellner, Daniel H. Sahlein, Justin Santarelli, Clemens M. Schirmer, Justin Singer, Jesse J. Liu, Aniel Q. Majjhoo, Thomas Wolfe, Neil V. Patel, Christopher Roark, Adnan H. Siddiqui
Journal: New England Journal of Medicine (2024)

Subacute and chronic subdural hematomas are common and frequently recur after surgical evacuation. The effect of adjunctive middle meningeal artery embolization on the risk of reoperation remains unclear. In a prospective, multicenter, interventional, adaptive-design trial, we randomly assigned patients with symptomatic subacute or chronic subdural hematoma with an indication for surgical evacuation to undergo middle meningeal artery embolization plus surgery (treatment group) or surgery alone (control group). The primary end point was hematoma recurrence or progression that led to repeat surgery within 90 days after the index treatment. The clinical secondary end point was deterioration of neurologic function at 90 days, which was assessed with the modified Rankin scale in a noninferiority analysis (margin for risk difference, 15 percentage points). A total of 197 patients were randomly assigned to the treatment group and 203 to the control group. Surgery occurred before randomization in 136 of 400 patients (34.0%). Hematoma recurrence or progression leading to repeat surgery occurred in 8 patients (4.1%) in the treatment group, as compared with 23 patients (11.3%) in the control group (relative risk, 0.36; 95% confidence interval [CI], 0.11 to 0.80; P = 0.008). Functional deterioration occurred in 11.9% of the patients in the treatment group and in 9.8% of those in the control group (risk difference, 2.1 percentage points; 95% CI, -4.8 to 8.9). Mortality at 90 days was 5.1% in the treatment group and 3.0% in the control group. By 30 days, serious adverse events related to the embolization procedure had occurred in 4 patients (2.0%) in the treatment group, including disabling stroke in 2 patients; no additional events had occurred by 180 days. Among patients with symptomatic subacute or chronic subdural hematoma with an indication for surgical evacuation, middle meningeal artery embolization plus surgery was associated with a lower risk of hematoma recurrence or progression leading to reoperation than surgery alone. Further study is needed to evaluate the safety of middle meningeal artery embolization in the management of subdural hematoma. (Funded by Medtronic; EMBOLISE ClinicalTrials.gov number, NCT04402632.).
Older age but not comorbidity is associated with worse survival in patients with hepatocellular carcinoma
Authors: Mounika Kanneganti, Mohammed Al-Hasan, Samantha Bourque, Sneha Deodhar, Ju Dong Yang, Daniel Q Huang, Anand V Kulkarni, Purva Gopal, Neehar D Parikh, Fasiha Kanwal, Madhukar S Patel, Amit G Singal
Journal: Clinical Gastroenterology and Hepatology (2024)
Prognostic significance of mutation type and chromosome fragility in Fanconi anemia
Authors: María José Ramírez, Roser Pujol, Jordi Minguillón, Massimo Bogliolo, Ilaria Persico, Debora Cavero, Aurora de la Cal, Paula Río, Susana Navarro, José Antonio Casado, Almudena Bailador, Antonio Sanchez de la Fuente, Miguel López de Heredia, Francisco Almazán, M. Luisa Antelo, Bienvenida Argilés, Isabel Badell, Marta Baragaño, Cristina Beléndez, Mar Bermúdez, Marta Bernués, María Isabel Buedo, Estela Carrasco, Albert Català, Dolors Costa, Isabel Cuesta, Rafael Fernandez‐Delgado, Ana Fernández‐Teijeiro, Ángela Figuera, Marta García, Ainhoa Gondra, Macarena González, Soledad González Muñiz, Ines Hernández‐Rodríguez, Fátima Ibañez, Nicholas John Kelleher, Francisco Lendínez, Mónica López, Ricardo López‐Almaraz, Inmaculada Marchante, Carmen Mendoza, José Nieto, Emilio Ojeda, Salvador Payán‐Pernía, Irene Peláez, Inmaculada Pérez de Soto, Raquel Portugal, María A. Ramos‐Arroyo, Alexandra Regueiro, Ana Rodríguez, Jordi Rosell, Raquel Saez, José Sánchez, Martha Sánchez, MªLeonor Senent, María Tapia, Juan Pablo Trujillo‐Quintero, José Manuel Vagace, Jaime Verdú‐Amorós, Victória Verdugo, Isabel Vidales, Jasson Villarreal, Cristina Díaz‐de‐Heredia, Julián Sevilla, Juan Antonio Bueren, Jordi Surrallés
Journal: American Journal of Hematology (2024)

Abstract Fanconi anemia (FA) is a rare genetic disease characterized by high phenotypic and genotypic heterogeneity, and extreme chromosome fragility. To better understand the natural history of FA, identify genetic risk and prognostic factors, and develop novel therapeutic strategies, the Spanish Registry of Patients with FA collects data on clinical features, chromosome fragility, genetic subtypes, and DNA sequencing with informed consent of participating individuals. In this article, we describe the clinical evolution of 227 patients followed up for up to 30 years, for whom our data indicate a cumulative cancer incidence of 86% by age 50. We found that patients with lower chromosome fragility had a milder malformation spectrum and better outcomes in terms of later‐onset hematologic impairment, less severe bone marrow failure, and lower cancer risk. We also found that outcomes were better for patients with mutations leading to mutant FANCA protein expression (genetic hypomorphism) than for patients lacking this protein. Likewise, prognosis was consistently better for patients with biallelic mutations in FANCD2 (mainly hypomorphic mutations) than for patients with biallelic mutations in FANCA and FANCG , with the lack of the mutant protein in patients with biallelic mutations in FANCG contributing to their poorer outcomes. Our results regarding the clinical impact of chromosome fragility and genetic hypomorphism suggest that mutant FA proteins retain residual activity. This finding should encourage the development of novel therapeutic strategies aimed at partially or fully enhancing mutant FA function, thereby preventing or delaying bone marrow failure and cancer in patients with FA. Clinical Trial Registration number: NCT06490510.
A Cross-Sectional Study of Physiologic Volar Melanotic Macules: Demographic, Historical, Clinical and Dermatoscopic Features of a Common yet Neglected Pigmentary Variant in Individuals with Skin of Color
Authors: Jonathan D Ho, Yu-Feng Chang, Andrew Tw Burton, Tashema Edwards, Peter C Chien, Dhruv Patel, Vaishnavee Wagh, Hye Jin Chung
Journal: Journal of the American Academy of Dermatology (2024)
Purinergic receptor P2X7 regulates interleukin-1α mediated inflammation in chronic kidney disease in a reactive oxygen species-dependent manner.
Authors: Maryam Amini, Janina Frisch, Priska Jost, Tamim Sarakpi, Simina-Ramona Selejan, Ellen Becker, Alexander Sellier, Jutta Engel, Michael Böhm, Mathias Hohl, Heidi Noels, Christoph Maack, Stefan Schunk, Leticia Prates Roma, Barbara A Niemeyer, Thimoteus Speer, Dalia Alansary
Journal: Kidney International (2024)
In Situ molecular profiles of glomerular cells by integrated imaging mass spectrometry and multiplexed immunofluorescence microscopy
Authors: Allison B Esselman, Felipe A Moser, Léonore Tideman, Lukasz G Migas, Katerina V Djambazova, Madeline E Colley, Ellie L Pingry, Nathan Heath Patterson, Melissa A Farrow, Haichun Yang, Agnes B Fogo, Mark de Caestecker, Raf Van de Plas, Jeffrey M Spraggins
Journal: Kidney International (2024)
Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial
Authors: Kevin N Sheth, Gregory W Albers, Jeffrey L Saver, Bruce C V Campbell, Bradley J Molyneaux, H E Hinson, Charlotte Cordonnier, Thorsten Steiner, Kazunori Toyoda, Max Wintermark, Ross Littauer, Jessica Collins, Nisha Lucas, Raul G Nogueira, J Marc Simard, Michael Wald, Kate Dawson, W Taylor Kimberly
Journal: The Lancet Neurology (2024)
Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study
Authors: Emily K Schworer, Matthew D Zammit, Jiebiao Wang, Benjamin L Handen, Tobey Betthauser, Charles M Laymon, Dana L Tudorascu, Annie D Cohen, Shahid H Zaman, Beau M Ances, Mark Mapstone, Elizabeth Head, Bradley T Christian, Sigan L Hartley
Journal: The Lancet Neurology (2024)
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, randomised trial
Authors: Qingyuan Liu, Shaohua Mo, Jun Wu, Xianzeng Tong, Kaiwen Wang, Xu Chen, Shanwen Chen, Shuaiwei Guo, Xiong Li, Mingde Li, Lei Peng, Xinguo Sun, Yang Wang, Jianjun Sun, Jun Pu, Kaige Zheng, Jiaming Zhang, Yang Liu, Yi Yang, Zheng Wen, Xin Nie, Yinghe Feng, Chuanjin Lan, Haishuang Tang, Nuochuan Wang, Jiangan Li, Zengli Miao, Xiaojie Lu, Bo Ning, Bing Zhao, Dezhi Kang, Xiaolin Chen, Yanan Zhang, Yan Zhang, Anxin Wang, Chengcheng Zhu, Yoshio Araki, Kenji Uda, Shinichi Yoshimura, Kazutaka Uchida, Takeshi Morimoto, Hideyuki Yoshioka, David Hasan, Rose Du, Michael R Levitt, Yong Cao, Shuo Wang, Jizong Zhao
Journal: The Lancet Neurology (2024)
Learning from the EHR to implement AI in healthcare
Authors: Christian Rose, Jonathan H. Chen
Journal: npj Digital Medicine (2024)

The introduction of the electronic health record was heralded as a technology solution to improve care quality and efficiency, but these tools have contributed to increased administrative burden and burnout for clinicians. Today, artificial intelligence is receiving much of the same attention and promises as electronic health records. Can healthcare learn from the failures of electronic health records to maximize the potential of artificial intelligence?
Embolization of the Middle Meningeal Artery for Chronic Subdural Hematoma
Authors: David Fiorella, Stephen J Monteith, Ricardo Hanel, Benjamin Atchie, SoHyun Boo, Ryan A McTaggart, Alois Zauner, Stavropoula Tjoumakaris, Charlotte Barbier, Ronald Benitez, Laurent Spelle, Laurent Pierot, Joshua A Hirsch, Michael Froehler, Adam S Arthur
Journal: New England Journal of Medicine (2024)

BackgroundPatients receiving standard treatment for chronic subdural hematoma have a high risk of treatment failure. The effect of adjunctive middle meningeal artery embolization on the risk of treatment failure in this population remains unknown.MethodsWe randomly assigned patients with symptomatic chronic subdural hematoma to undergo middle meningeal artery embolization as an adjunct to standard treatment (embolization group) or to receive standard treatment alone (control group). Either surgical or nonsurgical standard treatment had been chosen for each patient before randomization. The primary efficacy outcome was a composite of the following events: recurrent or residual chronic subdural hematoma (measuring >10 mm) at 180 days; reoperation or surgical rescue within 180 days; or major disabling stroke, myocardial infarction, or death from neurologic causes within 180 days. The primary safety outcome was a composite of major disabling stroke or death from any cause within 30 days.ResultsAmong 310 enrolled patients, 149 were randomly assigned to the embolization group and 161 to the control group; 189 patients were to receive surgical standard treatment and 121 nonsurgical standard treatment. The mean age of the patients was 73 years, and 70% were men. In the primary efficacy analysis, a primary-outcome event occurred in 19 of 120 patients (16%) in the embolization group, as compared with 47 of 129 patients (36%) in the control group (odds ratio, 0.36; 95% confidence interval, 0.20 to 0.66; P=0.001). In the primary safety analysis, 4 of 144 patients (3%) in the embolization group and 5 of 166 patients (3%) in the control group either had a major disabling stroke or died within 30 days. Through 180 days, 12 patients (8%) in the embolization group and 9 patients (5%) in the control group had died, with death from neurologic causes occurring in 1 patient (1%) in the embolization group and in 3 patients (2%) in the control group.ConclusionsAmong patients with symptomatic chronic subdural hematoma, adjunctive middle meningeal artery embolization resulted in a lower risk of treatment failure than standard treatment alone, without resulting in an increased incidence of disabling stroke or death in the short term. Further study of longer-term safety outcomes is warranted. (Funded by Balt USA; STEM ClinicalTrials.gov number, NCT04410146.)
The genomic portrait of the Picene culture provides new insights into the Italic Iron Age and the legacy of the Roman Empire in Central Italy
Authors: Francesco Ravasini, Helja Kabral, Anu Solnik, Luciana de Gennaro, Francesco Montinaro, Ruoyun Hui, Chiara Delpino, Stefano Finocchi, Pierluigi Giroldini, Oscar Mei, Michael Allen Beck De Lotto, Elisabetta Cilli, Mogge Hajiesmaeil, Letizia Pistacchia, Flavia Risi, Chiara Giacometti, Christiana Lyn Scheib, Kristiina Tambets, Mait Metspalu, Fulvio Cruciani, Eugenia D’Atanasio, Beniamino Trombetta
Journal: Genome biology (2024)

The Italic Iron Age is characterized by the presence of various ethnic groups partially examined from a genomic perspective. To explore the evolution of Iron Age Italic populations and the genetic impact of Romanization, we focus on the Picenes, one of the most fascinating pre-Roman civilizations, who flourished on the Middle Adriatic side of Central Italy between the 9th and the 3rd century BCE, until the Roman colonization. More than 50 samples are reported, spanning more than 1000 years of history from the Iron Age to Late Antiquity. Despite cultural diversity, our analysis reveals no major differences between the Picenes and other coeval populations, suggesting a shared genetic history of the Central Italian Iron Age ethnic groups. Nevertheless, a slight genetic differentiation between populations along the Adriatic and Tyrrhenian coasts can be observed, possibly due to different population dynamics in the two sides of Italy and/or genetic contacts across the Adriatic Sea. Additionally, we identify several individuals with ancestries deviating from their general population. Lastly, in our Late Antiquity site, we observe a drastic change in the genetic landscape of the Middle Adriatic region, indicating a relevant influx from the Near East, possibly as a consequence of Romanization. Our findings, consistently with archeological hypotheses, suggest genetic interactions across the Adriatic Sea during the Bronze/Iron Age and a high level of individual mobility typical of cosmopolitan societies. Finally, we highlight the role of the Roman Empire in shaping genetic and phenotypic changes that greatly impact the Italian peninsula.
Procedural outcomes of a novel underwater injection endoscopic mucosal resection technique for colorectal polyps ≥10 mm (with video)
Authors: Yuichiro Hirai, Naoya Toyoshima, Hiroyuki Takamaru, Masau Sekiguchi, Masayoshi Yamada, Nozomu Kobayashi, Shigeki Sekine, Yutaka Saito
Journal: Endoscopy (2024)

Background and Aims It is uncertain whether underwater EMR (U-EMR) enables resection of the submucosal tissue with sufficient margins for T1 colorectal cancer (T1-CRC) because U-EMR forgoes submucosal injection. Therefore, we developed a novel ‘underwater injection EMR (UI-EMR)’ method that combines submucosal injection with U-EMR to obtain adequate vertical margin (VM). Patients and methods We retrospectively analyzed procedure-related outcomes of 135 consecutive lesions from patients who underwent UI-EMR for ≥10 mm, non-pedunculated colorectal polyps (median lesion size; 15 mm). The outcomes included en bloc, R0, RX, R1 resection rates and adverse events. Additionally, the VM distance of seven T1-CRCs was evaluated. Results En bloc resection was achieved in 127 lesions (94.1%). R0 and RX resection were observed in 92 (68.2%) and 42 lesions (31.1%), respectively, while R1 resection was seen in only one lesion (0.7%). We identified two lesions (1.5%) with adverse events, which were delayed bleeding. In T1-CRCs, all seven cases had free VMs, and the median VM distance was 1140 µm (range, 731-1570 µm). Conclusions UI-EMR safely demonstrated high success rates for en bloc resection, and potentially ensures sufficient VM. This technique might become an option, particularly for relatively small lesions concerning for T1-CRC and deserve further study.
Cost-effectiveness of viral load testing for transitioning antiretroviral therapy-experienced children to dolutegravir in South Africa: a modelling analysis
Authors: Isaac Ravi Brenner, Clare F Flanagan, Martina Penazzato, Karen A Webb, Stephanie B Horsfall, Emily P Hyle, Elaine Abrams, Jason Bacha, Anne M Neilan, Intira Jeannie Collins, Sophie Desmonde, Siobhan Crichton, Mary-Ann Davies, Kenneth A Freedberg, Andrea L Ciaranello
Journal: The Lancet Global Health (2024)
Postpartum maternal and infant haematological effects of second-trimester ferric carboxymaltose versus standard-of-care oral iron in Malawi: longitudinal follow-up of a randomised controlled trial
Authors: Glory Mzembe, Ernest Moya, Martin N Mwangi, Ricardo Ataide, Rebecca Harding, Justina Kaunda, Truwah Zinenani, Gomezgani Mhango, William Stones, Owen Mtambo, Ayse Y Demir, Hans Verhoef, Sabine Braat, Sant-Rayn Pasricha, Kamija S Phiri
Journal: The Lancet Global Health (2024)
National and subnational burden of mental disorders in Iran (1990–2019): findings of the Global Burden of Disease 2019 study
Authors: Leila Ghalichi, Seyed Vahid Shariat, Morteza Naserbakht, Mozhgan Taban, Mohsen Abbasi-Kangevari, Fatemeh Afrashteh, Marjan Ajami, Hossein Akbarialiabad, Sohrab Amiri, Jalal Arabloo, Hosein Azizi, Nayereh Baghcheghi, Sara Bagherieh, Saeid Bitaraf, Sharareh Eskandarieh, Fataneh Ghadirian, Ali Gholami, Pouya Goleij, Mojtaba Habibi Asgarabad, Aram Halimi, Mohammad Heidari, Farideh Iravanpour, Roxana Jabbarinejad, Morteza Jafarinia, Hamid Reza Khayat Kashani, Hamid Reza Koohestani, Mohammad-Reza Malekpour, Mahsa Mayeli, Reza Mirfakhraie, Mojgan Mirghafourvand, Soheil Mohammadi, Esmaeil Mohammadi, Abdollah Mohammadian-Hafshejani, Fateme Montazeri, Majid Motaghinejad, Shumaila Nargus, Hassan Okati-Aliabad, Mohammad Taha Pahlevan Fallahy, Shayan Rahmani, Ali Rajabpour Sanati, Vahid Rashedi, Nazila Rezaei, Mohsen Rezaeian, Reihaneh Sadeghian, Saeid Sadeghian, Amirhossein Sahebkar, Saman Sargazi, Yaser Sarikhani, Mahan Shafie, Seyed-Amir Tabatabaeizadeh, Amir Tiyuri, Seyed Mohammad Vahabi, Rohollah Valizadeh, Leila Zaki, Iman Zare, Mohammad Zoladl, Maziar Moradi-Lakeh, Afarin Rahimi-Movaghar, Ali H Mokdad, Mohsen Naghavi
Journal: The Lancet Global Health (2024)
Lassa fever outbreaks, mathematical models, and disease parameters: a systematic review and meta-analysis
Authors: Patrick Doohan, David Jorgensen, Tristan M Naidoo, Kelly McCain, Joseph T Hicks, Ruth McCabe, Sangeeta Bhatia, Kelly Charniga, Gina Cuomo-Dannenburg, Arran Hamlet, Rebecca K Nash, Dariya Nikitin, Thomas Rawson, Richard J Sheppard, H Juliette T Unwin, Sabine van Elsland, Anne Cori, Christian Morgenstern, Natsuko Imai-Eaton
Journal: The Lancet Global Health (2024)
Understanding progress and challenges in women's health and wellbeing in exemplar countries: a time-series study identifying positive outliers
Authors: Ira Martopullo, Paulo A Neves, Sarah Baird, Mengjia Liang, Emily C Keats, Alina Cherkas, Aditi Iyer, Shreelata Rao Seshadri, Emily Woolway, Cesar G Victora, Gita Sen, Jennifer Kidwell Drake, Zulfiqar A Bhutta
Journal: The Lancet Global Health (2024)
The epidemiological benefit of pyrethroid–pyrrole insecticide treated nets against malaria: an individual-based malaria transmission dynamics modelling study
Authors: Thomas S Churcher, Isaac J Stopard, Arran Hamlet, Dominic P Dee, Antoine Sanou, Mark Rowland, Moussa W Guelbeogo, Basiliana Emidi, Jacklin F Mosha, Joseph D Challenger, Adrian Denz, Andrew Glover, Giovanni D Charles, Emma L Russell, Rich Fitzjohn, Pete Winskill, Christen Fornadel, Tom Mclean, Peder Digre, Joseph Wagman, Frank Mosha, Jackie Cook, Martin C Akogbéto, Luc S Djogbenou, Hilary Ranson, Philip McCall, Alphaxard Manjurano, Sagnon N'Falé, Natacha Protopopoff, Manfred Accrombessi, Corine Ngufor, Geraldine Foster, Ellie Sherrard-Smith
Journal: The Lancet Global Health (2024)
The association of HIV status with triple-negative breast cancer in patients with breast cancer in South Africa: a cross-sectional analysis of case-only data from a prospective cohort study
Authors: Jacob Dubner, Alfred I Neugut, Maureen Joffe, Daniel S O'Neil, Oluwatosin A Ayeni, Wenlong Carl Chen, Ines Buccimazza, Sharon R Čačala, Laura W Stopforth, Hayley A Farrow, Sarah Nietz, Nivashini Murugan, Boitumelo Phakathi, Judith S Jacobson, Katherine D Crew, Valerie McCormack, Paul Ruff, Herbert Cubasch, Yoanna S Pumpalova
Journal: The Lancet Global Health (2024)